Costanza Di Chiara

Dr. Costanza Di Chiara

University of Padua, Padua, Italy
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
Costanza Di ChiaraCostanza Di Chiara
Costanza Di Chiara
ACAnna Cantarutti
Anna Cantarutti
PCPaola Costenaro
Paola Costenaro
DDDaniele Donà
Daniele Donà
FBFrancesco Bonfante
Francesco Bonfante
CGCarlo Giaquinto
Carlo Giaquinto
The ongoing SARS-CoV-2 pandemic has afflicted public health care systems worldwide. Vaccination is one of the most effective tools to achieve herd immunity in a short period. Consequently, a deeper understanding of the mechanisms related to long-term kinetics and durability of the immune response against SARS-CoV-2 is vital in optimizing vaccination strategies. In this respect, the anti–receptor-binding domain (RBD) antibodies against SARS-CoV-2’s spike (S) protein, with their strong positive correlation with the neutralizing antibodies (NAbs), represent a reproducible, cost-effective, and precise tool to define the quality of the host's immune response against the virus.1-6 Currently, scientific knowledge investigating the long-term persistence of anti–SARS-CoV-2 antibodies up to 12 months after the infection is mainly limited to adults,7-15 whereas a gap concerning the pediatric population, which plays an essential role in silently spreading the virus,16,17 still remains. To date, few studies18-20 have reported on the production of NAbs and anti–S-RBD IgG up to 8 to 12 months after infection in children who had recovered from mild or asymptomatic COVID-19. To gain a greater understanding of the immune response in children after SARS-CoV-2 infection, we examine the long-term anti–S-RBD IgG kinetics in a prospective cohort of COVID-19 family clusters mostly affected by asymptomatic or mild disease.

1 September 2021 in Pediatrics
Verified
Journal Article
Closed access
PDF file
FBFrancesco Bonfante
Francesco Bonfante
PCPaola Costenaro
Paola Costenaro
ACAnna Cantarutti
Anna Cantarutti
Costanza Di ChiaraCostanza Di Chiara
Costanza Di Chiara
ABAlessio Bortolami
Alessio Bortolami
CGCarlo Giaquinto
Carlo Giaquinto
BACKGROUND: Recent evidence suggests that neutralizing antibodies (nAbs) to severe acute respiratory syndrome coronavirus 2 may persist over time; however, knowledge regarding pediatric subjects is limited. METHODS: A single-center, prospective observational study was conducted on 57 family clusters of coronavirus disease 2019, including children of neonatal and pediatric age attending the University Hospital of Padua (Italy). For each patient, blood samples were collected for both the quantification of nAbs through a plaque reduction neutralizing test and the detection of antinucleocapsid-spike protein immunoglobulin G and/or immunoglobulin M. RESULTS: We analyzed 283 blood samples collected from 152 confirmed coronavirus disease 2019 cases (82 parents and 70 children or older siblings of median age of 8 years, interquartile range: 4–13), presenting asymptomatic or with mildly symptomatic disease. Despite the decrease of immunoglobulin G over time, nAbs were found to persist up to 7 to 8 months in children, whereas adults recorded a modest declining trend. Interestingly, children aged <6 years, and, in particular, those aged <3 years, developed higher long-lasting levels of nAbs compared with older siblings and/or adults. CONCLUSIONS: Mild and asymptomatic severe acute respiratory syndrome coronavirus 2 infections in family clusters elicited higher nAbs among children.

10 February 2021 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Open access
Andrea PadoanAndrea Padoan
Andrea Padoan
FBFrancesco Bonfante
Francesco Bonfante
CCChiara Cosma
Chiara Cosma
Costanza Di ChiaraCostanza Di Chiara
Costanza Di Chiara
LSLaura Sciacovelli
Laura Sciacovelli
Mario PlebaniMario Plebani
Mario Plebani
Objectives: SARS-CoV-2 serology presents an important role in several aspects of COVID-19 pandemic. Immunoassays performances have to be accurately evaluated and correlated with neutralizing antibodies. We investigated the analytical and clinical performances of a SARS-CoV-2 RBD IgG assay, automated on a high throughput platform, and the correlation of the antibodies (Ab) levels with the plaque reduction neutralization (PRNT50) Ab titers. Methods: A series of 546 samples were evaluated by SARS-CoV-2 RBD IgG assay (Snibe diagnostics), including 171 negative and 168 positive SARS-CoV-2 subjects and a further group of 207 subjects of the COVID-19 family clusters follow-up cohort. Results: Assay imprecision ranged from 3.98 to 12.18% being satisfactory at low and medium levels; linearity was excellent in all the measurement range. Considering specimens collected after 14 days post symptoms onset, overall sensitivity and specificity were 99.0 and 92.5%, respectively. A total of 281 leftover samples results of the PRNT50 test were available. An elevated correlation was obtained between the SARS-CoV-2 RBD IgG assay and the PRNT50 titer at univariate (ρ=0.689) and multivariate (ρ=0.712) analyses. Conclusions: SARS-CoV-2 S-RBD IgG assay shows satisfactory analytical and clinical performances, and a strong correlation with sera neutralizing activity.

1 September 2020 in Journal of Hospital Infection
Verified
Journal Article
Closed access
DDDaniele Donà
Daniele Donà
Costanza Di ChiaraCostanza Di Chiara
Costanza Di Chiara
MSM. Sharland
M. Sharland

11 January 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Annalisa AstolfiAnnalisa Astolfi
Annalisa Astolfi
FCFrancesca Cipriani
Francesca Cipriani
DMDaria Messelodi
Daria Messelodi
MLMatilde De Luca
Matilde De Luca
VIValentina Indio
Valentina Indio
Andrea PESSIONAndrea PESSION
Andrea PESSION
Atopic dermatitis is frequently associated with the onset of other allergic conditions, such as asthma, rhino-conjunctivitis and food allergy. The etiology of atopic dermatitis is marginally understood in spite of the number of predisposing factors, above all, mutations in the Filaggrin gene (FLG). In this study, the association between loss-of-function variants in the FLG gene and other allergic manifestations, in particular food allergy, was evaluated in an Italian pediatric population affected by atopic dermatitis. The 10 more frequently mutated loci in the FLG gene were genotyped in 238 children affected by atopic dermatitis and tested for association with clinical features of allergic disorders by a multivariate logistic regression model. R501X and 2282del4 were the only two mutations identified; 12.2% of children carry one of these variants, corresponding to an allelic frequency of 6.5%. According to multivariate statistical analysis, loss-of-function variants in the FLG gene represent a risk factor for the onset of severe manifestations of food allergy (OR = 8.9; CI: 3.1–28.3). Peanut and hazelnut were identified as high-risk foods in patients with FLG mutations. This study demonstrates that atopic children carrying FLG mutations represent a high-risk population due to their predisposition to develop severe food allergy reactions, such as anaphylaxis.

24 December 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
EBElisa Barbieri
Elisa Barbieri
Costanza Di ChiaraCostanza Di Chiara
Costanza Di Chiara
PCPaola Costenaro
Paola Costenaro
Anna CantaruttiAnna Cantarutti
Anna Cantarutti
CGCarlo Giaquinto
Carlo Giaquinto
DDDaniele Donà
Daniele Donà
Comprehensive data are needed to monitor antibiotic prescribing and inform stewardship. We aimed to evaluate the current antibiotic prescribing patterns, including treatment switching and prolongation, in the paediatric primary care setting in Italy. This database study assessed antibiotic prescriptions retrieved from Pedianet, a paediatric primary care database, from 1 January 2012 to 31 December 2018. Descriptive analyses were stratified by diagnosis class, calendar year, and children’s age. Generalized linear Poisson regression was used to assess variation in the prescriptions. In total, 505,927 antibiotic prescriptions were included. From 2012 to 2018, the number of antibiotics per child decreased significantly by 4% yearly from 0.79 in 2012 to 0.62 in 2018. Amoxicillin prescriptions decreased with increasing children’s age, while macrolides and third-generation cephalosporins had the opposite trend. Prescriptions were associated with a diagnosis of upper respiratory infection in 23% of cases, followed by pharyngitis (21%), bronchitis and bronchiolitis (12%), and acute otitis media (12%). Eight percent of treatment episodes were prolonged or switched class, mostly represented by co-amoxiclav, macrolides, and third-generation cephalosporins. Our findings report an overall decrease in antibiotic prescriptions, but pre-schoolers are still receiving more than one antibiotic yearly, and broad-spectrum antibiotics prescription rates remain the highest.